Genesis Biosystems, Inc., headquartered in the United States, is a leading innovator in the medical device industry, specialising in advanced solutions for the healthcare sector. Founded in 2006, the company has established itself as a key player in the development of cutting-edge technologies for tissue regeneration and wound care. With a focus on products such as the innovative Genesis® System, Genesis Biosystems offers unique, evidence-based solutions that enhance patient outcomes and streamline clinical workflows. The company’s commitment to quality and innovation has earned it a strong market position, recognised for its contributions to improving healthcare delivery. As it continues to expand its operational reach, Genesis Biosystems remains dedicated to advancing the field of regenerative medicine.
How does Genesis Biosystems, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Genesis Biosystems, Inc.'s score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Genesis Biosystems, Inc. reported total emissions of approximately 686,600 kg CO2e, comprising 404,000 kg CO2e from Scope 1 and 282,600 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Comparatively, in 2021, the organisation's Scope 1 emissions were significantly higher at approximately 533 million kg CO2e, indicating a substantial reduction in direct emissions over the year. However, there are no specific reduction targets or climate pledges outlined in their current commitments. Genesis Biosystems, Inc. does not inherit emissions data from any parent organisation, and all reported figures are derived solely from their own operations. The company continues to focus on improving its emissions profile, although further details on specific initiatives or future targets are not available at this time.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genesis Biosystems, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.